给药方案

  • 网络regimen;dosing regimen;dose regimen;drug regimen;dosage regimen
给药方案给药方案
  1. 运用Excel表格程序设计静脉滴注的给药方案

    The dosage regimen design of intravenous administration based on Microsoft Excel

  2. 基于Excel函数设计抗菌药物间歇静脉滴注给药方案

    Excel-based Design of Intermittent Intravenous Drip Dose Regimen of Antibiotics

  3. Excel联合VISUALBASIC辅助制定一室模型静脉推注给药方案设计

    Dosage regimen design of multiple dosing intravenous administration of One-compartment model based on Microsoft Excel and Visual Basic

  4. Bayesian一点法研究心衰患者的地高辛临床药物动力学及给药方案

    Study on clinical pharmacokinetics and dosage regimens of digoxin by one - point Bayesian approach

  5. B组69例采用14d个体化给药方案。

    Group B ( 69 clients ) was treated by 14 d individualized dosing schedule .

  6. 目的:测定帕珠沙星对社区获得性感染(CAI)常见致病菌PK/PD,为临床制定合理给药方案提供参考依据。

    Objective : To study PK / PD of pazufloxacin against pathogen of community acquired infection ( CAI ) .

  7. 中药TDM及其在个体化给药方案中的应用

    TDM of traditional Chinese medicine and the application in individualized administration

  8. 方法:用Excel软件编写基于药动学参数的给药方案设计程序。

    METHODS : microsoft Excel was used to write a program by the pharmacokinetic parameters to show the dosage regimen .

  9. 结论用Bayesian反馈法估算个体药代动力学参数及预测血药浓度,可满足临床优化个体化给药方案的需要。

    CONCLUSION Bayesian approach is suitable for estimating individual pharmacokinetic parameters , forecasting plasma concentration and optimizing individual dosage regimens .

  10. 其次,对那些未行PCI的患者,标准剂量给药方案已经足够;

    Secondly , for those patients who do not undergo PCI , the standard dose regimen of clopidogrel is sufficient .

  11. 结论:通过测定CA制定VP16给药方案是可行的。

    CONCLUSION : It is feasible to adjust the therapeutic regimen of VP16 by determining CA.

  12. 结论:确定学龄儿童CA分布情况及其正常值范围,可为制定儿童个体化给药方案和给药剂量提供依据。

    Conclusion : It is useful to determine the distribution of CA and the normal value range of CA in Shanghai school-age children for individual dosage regimen .

  13. 万古霉素不同给药方案对MRSA大鼠肺炎模型的疗效观察及耐药性研究

    Effects and Drug Resistances of Vancomycin Administered in Different Dosage in Rats MRSA Pneumonia Model

  14. 合理的给药方案是尽可能延长血药浓度高于MIC的时间。

    Rational plan of giving medicine is to prolong the time of drug blood concentration which is longer than that of MIC .

  15. CsA血药浓度监测对制定给药方案、肾毒性和排斥反应的鉴别,有重要的临床意义。

    CsA therapeutic drug monitoring has great significance on drafting the clinical protocols for CsA and differentiation of the nephrotoxicity and allograft rejection .

  16. 方法根据四阶Runge-Kutta算法,采用Excel软件编写基于药动学参数的给药方案设计程序。

    Methods According to the four-stage Runge-Kutta algorithm , we used Microsoft Excel to write a design program for dosage regime based on pharmacokinetic parameters .

  17. 结论大剂量MTX化疗时,有必要进行血药浓度监测,以制定个体化给药方案,从而将MTX剂量增至患儿可耐受剂量。

    CONCLUSION It 's necessary to determine individual remedy by serum concentration monitoring for adding MTX dosage to the extent that can be tolerated by ALL children .

  18. 因此,抗癌药物联合用药时,应以AUC、T_(1/2)、C_(ss)为指标调整给药方案。

    Therefore , dosage regimen should be adjusted in accordance with AUC , T_ ( 1 / 2 ) and c_ ( ss ) in combined anticancer drugs .

  19. 通过比较得到更优的给药方案,并将优化给药方案应用于临床病例中,观察临床疗效。结果:1.对于肠杆菌科细菌,碳青霉烯类抗生素能获得理想的CFR。

    Then we applied optimum regimen to clinic and observed clinical therapeutic effect . Results : 1.Against Enterobacteriaceae , carbapenems attained optima CFR .

  20. 多剂量给药方案按q8h共服药10次。

    Multiple-dose regimens used 8-hour dosing intervals for 10 doses .

  21. 目的研究促性腺激素释放激素激动剂(GnRH-a)延长间隔给药方案治疗子宫腺肌病的疗效。

    Objective To study the effects of an extended-interval dosing regimen of gonadotropin releasing hormone agonist ( GnRH-a ) in the treatment of adenomyosis .

  22. 目的考察肾移植患者口服普乐可复(FK506)胶囊常规监测群体药代动力学特征,为临床调整个体化给药方案提供依据。

    Objective To evaluate the population pharmacokinetic character of orally tacrolimus ( FK506 ) from routine drug monitoring data after renal transplantation and to provide the evidence of the schedule of individual dosage .

  23. 目的:研究单剂量肌肉注射氨甲蝶呤(MTX)治疗异位妊娠(EP)的药动学及药效学,为给药方案的选择提供理论依据。

    OBJECTIVE : To study the pharmacokinetics and pharmacodynamics of single dose of intramuscularly injected methotrexate ( MTX ) in the treatment of ectopic pregnancy so as to provide theoretical bases for the choice dosage regimen .

  24. 目的:调查门急诊病人静脉滴注使用抗菌药物不良反应(ADR)的发生率、临床表现及相关因素,探讨抗菌药物的合理给药方案。

    Objective : To investigate the adverse drug reaction ( ADR ) rates , clinical manifestations and related factors in the outpatients who had been treated with antibacterials by intravenous drip , and to guide rational drug use .

  25. 目的观察泰索帝(Taxotere)2周给药方案治疗晚期乳腺癌的临床疗效和毒性反应。

    Objective To observe the response and toxic reaction of Taxotere administered by two consecutive weekly infusions in the treatment of advanced breast cancer .

  26. 方法:建立急性耐力运动大鼠的动物模型、制定中药制剂与给药方案、检测大鼠端脑一氧化氮、多巴胺和去甲肾上腺素(norepinephrine,NE)。

    METHODS : Rat model of acute endurance exercise was established , and traditional Chinese medicine agent and dosing prescription were made up . Levels of NO , dopam ine ( DA ) and norepinephrine ( NE ) were measured .

  27. 目的通过测定奈替米星(NTA)两种给药方案的体内杀菌活性及血药浓度,观察不同给药方案预防感染的疗效与副作用,优选其最佳给药方案。

    Objective To determine the optimum administration modality of netilmicin ( NTM ) by comparing the blood concentration , bactericidal activity , clinical effect and adverse reactions at two different regimen .

  28. 方法将140例围绝经期和绝经后妇女随机分为4组,给药方案分别是:A组(35例):每日戊酸雌二醇(E2V)1mg+醋酸甲羟孕酮(MPA)2mg;

    Methods One hundred and forty peri - and post - menopausal women were randomly divided into 4 groups : group A ( 35 cases ) received estradiol valerate ( E_2V ) 1 mg + medroxyprogesterone acetate ( MPA ) 2 mg per day ;

  29. 单剂量口服泛昔洛韦良好的耐受性和药动学特点的事实,推荐口服泛昔洛韦0-125g~0-75g、1日3次的给药方案用于临床可能是安全的。

    That fine tolerance to single dose of famciclovir and pharmacokinetic charateristics similar to Famvir showed that famciclovir in a dose of 0.125g ~ 0.75g , 3 times daily would be safe for clinical use .

  30. 结论:推注剂量和滴注速率对控制rHV-2水平起重要作用,这对临床试验优化给药方案有一定作用。

    CONCLUSION : Both the loading dose and the infusion rate are very important for controlling the rHV-2 level , and the data may be helpful for optimizing dosage-regimen in clinical trials .